Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Gains from Investment Securities (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Gains from Investment Securities for 4 consecutive years, with $137027.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 104.62% to $137027.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $137027.0, a N/A change, with the full-year FY2025 number at $91211.0, up 104.88% from a year prior.
  • Gains from Investment Securities was $137027.0 for Q3 2025 at Neuphoria Therapeutics, up from $91211.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $56.6 million in Q2 2022 to a low of -$3.0 million in Q3 2024.
  • A 4-year average of $12.3 million and a median of $137027.0 in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: tumbled 49.13% in 2023, then soared 104.62% in 2025.
  • Neuphoria Therapeutics' Gains from Investment Securities stood at $56.6 million in 2022, then crashed by 49.13% to $28.8 million in 2023, then crashed by 89.12% to $3.1 million in 2024, then crashed by 95.63% to $137027.0 in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Gains from Investment Securities are $137027.0 (Q3 2025), $91211.0 (Q2 2025), and $50854.0 (Q1 2025).